Price Alert

Kura Oncology Inc. (KURA)

NASDAQ: KURA · Real-Time Price · USD

8.13

-0.30 (-3.56%)

At close: Sep 04, 2025, 3:59 PM

8.50

4.55%

After-hours: Sep 04, 2025, 07:13 PM EDT

-3.56% (1D)

Bid	7.98
Market Cap	705.66M
Revenue (ttm)	83.28M
Net Income (ttm)	-197.17M
EPS (ttm)	-2.25
PE Ratio (ttm)	-3.61
Forward PE	-3.71
Analyst	Buy

Ask	8.37
Volume	1,589,681
Avg. Volume (20D)	1,802,436.5
Open	8.40
Previous Close	8.43
Day's Range	7.89 - 8.52
52-Week Range	5.41 - 21.40
Beta	0.40

About KURA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol KURA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for KURA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Kura Oncology Inc. is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+10.72%

Kura Oncology shares are trading higher after the ... Unlock content with Pro Subscription

7 months ago

-2.54%

Kura Oncology shares are trading lower. The company announced topline results from KOMET-001.

News

3 weeks ago · seekingalpha.com

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Brian T. Powl - Chief Commercial Officer Greg Mann - Corporate Participant Mollie Leo...

4 weeks ago · zacks.com

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

Kura Oncology (KURA) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of $0.15. This compares to a loss of $0.59 per share a year ago.

4 weeks ago · fool.com

Kura (KURA) Revenue Drops 61%

2 months ago · seekingalpha.com

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Kura Oncology is a Strong Buy due to ziftomenib's positive Phase 2 data in newly diagnosed AML mutant patients and upcoming FDA Priority Review for relapsed/refractory NPM1-m/KMT2A-r AML. The pipeline...